Rather than a binary choice—atherectomy or lithotripsy—the market for treating severely calcified lesions seems likely to evolve into a mixture of both technologies. 

Throughout its nearly 30-year history, atherectomy has remained something of an under-achiever.

Can a disruptive technology from the past become the nemesis of calcified lesions in the future?

The aging population plus increases in hypertension, diabetes and chronic kidney disease have contributed to more patients having severely calcified arterial lesions.